PMs must be ready to speak to the media at a moment’s notice—and have something to say.
With the Rise of GLP-1 Agonists for Treating Obesity, Will Access Challenges Prevent Progress?
JAMA commentary suggests that issues such as high costs, access, and equity will stop patients from obtaining GLP-1 agonists to treat obesity.
Recent Licensing Agreement Poised to Advance Company ADC
In an interview with PharmExec Associate Editor Don Tracy, Jingsong Wang discusses Nona Biosciences’ recent exclusive license agreement with Pfizer Inc. for the development and commercialization of HBM9033.
Bristol Myers Squibb Reveals Promising Results from Trial of Zeposia for Multiple Sclerosis
Phase III DAYBREAK study found consistent safety with Zeposia in patients with relapsing forms of multiple sclerosis.
Cell and Gene Therapy Check-in 2024
Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.
CDC’s Advisory Committee Recommends Another Round of Covid-19 Shots for Seniors
The agency updated its recommendations after a vote by the ACIP advisory committee.
Biosimilars Report Shows Challenges, Opportunities Across Disease States
Cardinal Health report highlights new biosimilar treatments, legislative developments, and multiple industry perspectives.
2 Commerce Drive Cranbury, NJ 08512